Heterogeneity of Adenosine Triphosphate-Based Chemotherapy Response Assay in Colorectal Cancer - Secondary Publication.
10.3349/ymj.2009.50.5.697
- Author:
Jung Wook HUH
1
;
Yoon Ah PARK
;
Kang Young LEE
;
Seung Kook SOHN
Author Information
1. Department of Surgery, Chonnam National University Hwasun Hospital and Medical School, Gwangju, Korea.
- Publication Type:Original Article ; Evaluation Studies
- Keywords:
Adenosine triphosphate;
chemotherapy response assay;
colorectal cancer
- MeSH:
Adenocarcinoma/*drug therapy;
Adenosine Triphosphate/*metabolism;
Adult;
Aged;
Aged, 80 and over;
Antineoplastic Agents/*pharmacology/therapeutic use;
Colorectal Neoplasms/*drug therapy;
Drug Screening Assays, Antitumor/*methods;
Female;
Humans;
Individualized Medicine;
Male;
Middle Aged;
Tumor Cells, Cultured
- From:Yonsei Medical Journal
2009;50(5):697-703
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) is a well-documented and validated technology that can individualize chemotherapy for patients with lung, stomach, or breast cancer. This study explored the feasibility of ATP-CRA as a chemosensitivity test in patients with colorectal cancer. MATERIALS AND METHODS: A total of 118 patients who underwent surgical resection for colorectal adenocarcinoma were analyzed for chemosensitivity to 6 anticancer drugs using ATP-CRA. We calculated the cell death rate (CDR) by measuring intracellular ATP levels of drug-exposed cells and untreated controls. RESULTS: Interpretable results were available for 85.5% (118/138) of patients. The mean coefficient of variation for triplicate ATP measurements was 9.2%. The highest CDR was observed in irinotecan (34.0%) and the lowest CDR in etoposide (21.0%). Paclitaxel had the broadest range of CDR (0-86.7%) and 5-FU had the narrowest range of CDR (0-56.8%). The overall highest responsiveness was seen most prevalently in irinotecan (24.7%, 23/93 patients). Irinotecan had the greatest responsiveness in patients with well differentiated and moderately differentiated carcinoma. CONCLUSION: Our study suggests that ATP-CRA could be used to identify patients with colorectal cancer who might benefit from treatment with a specific chemotherapeutic agent.
